Notification of Half Year Results

Alliance Pharma PLC

10 August 2023

 

For immediate release

10 August 2023

ALLIANCE PHARMA PLC

("Alliance", "Company" or the "Group")

Notification of Half Year Results

Alliance Pharma plc (AIM: APH), the international consumer healthcare company, announces a change of date for the publication of its results for the six months ended 30 June 2023. The interim results will be released on Tuesday 26 September 2023.

A meeting for analysts will be held at 9:30am on 26 September 2023 at Buchanan, 107 Cheapside, London EC2V 6DN. To register for the meeting, analysts should contact Buchanan at [e-mail].

A live webcast of the analyst meeting will be accessible via the following link:

https://stream.buchanan.uk.com/broadcast/64d35bfa8964824b00aaa7a0

Following the meeting, a replay of the webcast will be made available at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors/,

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
[e-mail]
Numis Securities Limited (Nominated Adviser and Joint Broker)	+ 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker)	+ 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END